New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
15:01 EDTPRGO, CPIXPerrigo confirms settlement of generic version of Acetadote patent litigation
Perrigo (TASE) announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote injection brought by Cumberland Pharmaceuticals (CPIX). Under the terms of the settlement, Perrigo can launch a generic version of Acetadote injection upon expiration of the patents in May 2026. In addition, Perrigo entered into an agreement with Cumberland wherein Perrigo can distribute Cumberland sourced authorized generic product upon generic market formation. Acetadote injection, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury and has annual sales of approximately $41M, as measured by Wolters Kluwer. Perrigo's Chairman and CEO Joseph C. Papa stated, "This settlement is another example of our long-term investment in extended product development. As always, Perrigo is committed to making quality healthcare more affordable for our customers."
News For PRGO;CPIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:57 EDTPRGOPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
07:53 EDTPRGOPerrigo announces launch of generic version of Astellas' Protopic ointment
Perrigo announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic Ointment 0.1% and 0.03%. Shipments to our pharmacy customers have commenced. Protopic Ointment is indicated to treat moderate to severe eczema. Brand sales were approximately $176M over the last 52 weeks according to Symphony Health Solutions.
November 21, 2014
14:17 EDTPRGOPerrigo price target raised to $184 from $175 at CRT Capital
Subscribe for More Information
10:20 EDTPRGOHigh option volume stocks
Subscribe for More Information
November 20, 2014
20:07 EDTPRGOPerrigo 5.92M share Secondary priced at $152.00
Subscribe for More Information
10:33 EDTPRGOHigh option volume stocks
High option volume stocks: KBR LM PRGO CHRW DG ZMH LGF ZTS OSIR REGI
06:56 EDTPRGOPerrigo files to sell $900M in ordinary shares
Perrigo intends to use the net proceeds of the offering, together with the proceeds of other financing sources, to fund the cash consideration for its proposed acquisition of Omega Pharma Invest NV and to repay or refinance certain indebtedness of Perrigo and/or Omega. If the Acquisition is not consummated, then the net proceeds of the offering will be used for general corporate purposes. J.P. Morgan, Barclays and BofA Merrill Lynch are the joint book-running managers in the offering.
06:56 EDTPRGOPerrigo files automatic mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use